A registry analysis of 11,474 US kidney transplant recipients found similar median survival age with and without rapamycin. The authors say they saw no meaningful long-term survival improvement.
Source: Human observational study, 11,474 US kidney transplant recipients: 4,885 prescribed rapamycin and 6,589 not prescribed it, followed a median of 11 years. It followed people and found a link. A link is a lead, not proof that one thing causes the other.
What was found
After adjusting for differences between the groups, median survival age was 64.6 years in the rapamycin group and 64.3 years in the non-rapamycin group. The researchers describe these as statistically similar.
The 95% confidence interval for the difference was -1.6 to 2.0 years. The authors write that they did not observe a meaningful improvement in long-term survival with mTOR inhibition, the drug class that includes rapamycin.
During the study period, 6,443 people died.
How it was done
The researchers used US national organ transplant registry data. They compared survival ages of recipients who were prescribed rapamycin with those who were not.
Everyone included was alive with a functioning graft one year after transplant. The team used propensity score weighting to adjust for age, body mass index, diabetes and 15 other factors.
What it does not show
This was an observational registry analysis, not a randomized trial. People were not assigned to take rapamycin, so unmeasured differences between the groups could remain despite the adjustments.
All participants were kidney transplant recipients who take drugs to suppress the immune system. The findings may not apply to healthy people. The study does not test low or intermittent doses taken for longevity.
Where this fits
The result applies to kidney transplant recipients who were alive with a working graft at one year. It does not directly speak to healthy people taking rapamycin for longevity, and the source describes human research on the drug as limited. Readers can check whether any medicine they take, including rapamycin, was prescribed by a doctor and how it fits with their other medicines.
Read more: Supplement and medication interactions
Who was talking about it
- BoxLife Magazine on the news (2026-11-10): BoxLife Magazine reported on the longest human rapamycin study and what it found about survival. See the post
- Bioengineer.org on the news (2026-11-07): Bioengineer.org reported that a kidney transplant study found no longevity benefit from chronic rapamycin use. See the post
- GeroScience on journal (2026-11-05): GeroScience published a registry analysis finding rapamycin did not meaningfully improve median survival age in kidney transplant recipients. See the post
The source
This is news, reported from the source above. It is not medical advice and not a recommendation. Talk to your doctor or pharmacist before you change any medicine or supplement.